Satisfying unmet medical needs
Immedica (marinuspharma.com) scores 54 out of 100 on Brand Analyzer, placing it in the Early Stage tier among Healthcare brands, in the 3rd percentile of 13189 Healthcare brands.
Immedica is a pharmaceutical company founded in 2019 and headquartered in Paris, focused on bringing innovative treatments to patients with rare metabolic and rare neurological diseases. It operates in more than 50 countries, combining a strong patient focus with commercial performance to address areas of significant unmet medical need. The company serves patients and healthcare providers within the rare disease healthcare sector.
| Brand Name | Immedica |
|---|---|
| Domain | marinuspharma.com |
| Industry | Healthcare |
| Founded | 2019 |
| Headquarters | Paris |
| Main Competitors | BioMarin (84/100), Amicus Therapeutics (84/100), Recordati Rare Diseases (75/100), Swedish Orphan Biovitrum (Sobi) (89/100), Chiesi Global Rare Diseases (75/100), Alexion Pharmaceuticals (87/100), Ultragenyx Pharmaceutical (79/100), Takeda (Rare Diseases) (87/100) |
Moz Domain Authority 38/100 vs category average 41 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Ranked #2,821,963 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "We have an important role to fill in society in bringing new, innovative treatments to patients with diseases where the unmet medical need is large." (Meta description: 25 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Social footprint: verified profiles on X (Twitter), Facebook, Instagram; no detected presence on LinkedIn, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Immedica's main competitors in Healthcare: BioMarin (84/100), Amicus Therapeutics (84/100), Recordati Rare Diseases (75/100), Swedish Orphan Biovitrum (Sobi) (89/100), Chiesi Global Rare Diseases (75/100).
Sources: Brand Analyzer scan
Immedica has low AI-search visibility, scoring 24/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 22, recommendation 30). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Immedica official site
Immedica was founded in 2019. Immedica operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Immedica is headquartered in Paris. Immedica operates in the Healthcare category.
Sources: Wikidata
Immedica scores 30/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Immedica official site
Immedica is a pharmaceutical company founded in 2019 and headquartered in Paris. It is dedicated to developing and delivering treatments for patients with rare metabolic and rare neurological diseases, operating in more than 50 countries worldwide.
Sources: Immedica official site
Immedica brings innovative treatments to patients with rare metabolic and rare neurological diseases where unmet medical needs are significant. The company combines patient-focused initiatives with commercial operations to distribute these treatments across more than 50 countries.
Sources: Immedica official site
Immedica can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Immedica official site
Immedica is known for its focus on rare metabolic and rare neurological diseases, positioning itself as a dedicated pharmaceutical company addressing areas of high unmet medical need and operating internationally in over 50 countries.
Sources: Immedica official site
Immedica's offerings are used by patients affected by rare metabolic and rare neurological diseases, as well as the healthcare providers who treat them, across more than 50 countries.
Sources: Immedica official site
Immedica scores 24/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Immedica has a weak AI-visibility profile at 24/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (30/100) and its weakest is visibility (21/100). It benefits from a Wikidata knowledge-graph entry, a global traffic rank of #2,821,963 (Tranco) and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 38/100 and thin schema.org structured data.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Immedica: LiteCure (54/100), Jean Dyerson Counselling (54/100), MedPro Wound Care Services, LLC (54/100), Merritt Hawkins (54/100).
A step up - brands to learn from: Word of Mouth Technology (56/100), Werskincare (56/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.